Eiken Chemical Co., Ltd.
Fiscal 2027 Q2 Earnings Presentation
Revenue was 21,388 million yen (cumulative Q2 for FY2027, +4.7% YoY), but net income declined sharply to 1,125 million yen. The prior-year period included a one-off special gain, and with that no longer present profits decelerated. The company aims for mid-term growth through ROIC improvement, portfolio review, and strengthened partnerships. Shareholder returns are maintained and a new shareholder benefit program was announced.
Key Figures
- Revenue: 21,388 million yen
- Operating Income: 1,587 million yen
- Net Income Attributable to Owners of Parent: 1,125 million yen
AI要約
Performance Overview
Cumulative revenue for Q2 of the fiscal year ending March 2027 was 21,388 million yen (up 4.7% year-on-year), securing revenue growth. However, net income attributable to owners of parent was 1,125 million yen, marking a significant decline due to the absence of the prior-period special gain. By segment, growth was supported by fecal occult blood and tuberculosis gene test reagents and domestic medical devices, while gene-related businesses saw revenue declines due to the domestic infectious disease situation and patent fee impacts. The company is promoting ROIC improvement and CCC optimization.
Shareholder Returns and Growth Strategy
The shareholder return policy will be maintained, and a new shareholder benefit program has been established. Efforts will focus on improving ROIC and advancing the development pipeline, strengthening sales and supply systems through collaborations with Towns and Kyokuto Pharmaceutical Industrial Co., Ltd., and enhancing capital efficiency via CCC improvement. Under the mid-term plan 2030, the company will proceed with launches of new products such as the OC Sensor R70 and FER II to capture domestic and international colorectal cancer screening demand.
Revenue Trend
Operating Income Trend
Net Income Trend
Margin Analysis
Eiken Chemical Co., Ltd.
Company overview · Stock price · Financial data · All IR
